Cojocaru Inimoara Mihaela, Cojocaru M, Iliescu Iuliana, Botnaru Ludmila, Gurban Camelia Vidiţa, Sfrijan Felicia, Tănăsescu R
"Carol Davila" University of Medicine and Pharmacy, Department of Neurology, "Colentina" Clinical Hospital, Bucharest, Romania.
Rom J Intern Med. 2010;48(1):101-4.
Myeloperoxidase (MPO) is a glycoprotein released by activated polymorphonuclear neutrophils, which takes part in the defence of the organism through production of hypochlorous acid (HOCl), a potent oxidant. MPO has a role in pathogenesis of atherosclerosis. The aim of the study was to evaluate the time course of MPO plasma levels in the early stage of ischemic stroke. The study included 78 patients with acute ischemic stroke, 46 females and 32 males, mean age 74.3 +/- 6.8 years. Blood samples for MPO measurement were taken within 24 hours after the onset of ischemic stroke. Seventy-two patients served as matched controls 43 females and 29 males, mean age 71.3 +/- 6.4 years. MPO was measured in plasma using the Abbott Architect platform (Abbott Diagnostics Inc., Abbott Parck IL). Comparisons between patients and controls and patients group were expressed as relative risk with its 95% confidence interval (RR [95% CI]), where a lower limit > 1.0 was considered significant. All p values were determined by Fischer's exact test. A value of p < 0.05 was considered statistically significant. Mean plasma MPO level was in patients with acute ischemic stroke 583 +/- 48 pmol/L. Seventy-one patients out of seventy-eight patients with ischemic stroke presented mean plasma MPO levels greater than the upper of normal (425 +/- 36 pmol/L, p < 0.0001, (RR 8.188, [95% CI 4.038 to 16.600]). Twelve controls presented mean plasma MPO level greater than the upper of normal. In conclusion, plasma MPO levels were statistically significantly higher in patients after ischemic stroke as compared to controls. MPO has been associated with acute ischemic stroke but its direct role in its pathogenesis has not been established. MPO could be proposed as a potential prognostic marker of such lesions rather than a marker of diagnosis. MPO is a new biomarker and a possible future therapeutic target.
髓过氧化物酶（MPO）是一种由活化的多形核中性粒细胞释放的糖蛋白，它通过产生次氯酸（HOCl，一种强效氧化剂）参与机体的防御。MPO在动脉粥样硬化的发病机制中起作用。本研究的目的是评估缺血性中风早期MPO血浆水平的时间进程。该研究纳入了78例急性缺血性中风患者，其中46例女性，32例男性，平均年龄74.3±6.8岁。在缺血性中风发作后24小时内采集用于MPO测量的血样。72例患者作为匹配对照，其中43例女性，29例男性，平均年龄71.3±6.4岁。使用雅培Architect平台（雅培诊断公司，伊利诺伊州雅培公园）测量血浆中的MPO。患者与对照以及患者组之间的比较以相对风险及其95%置信区间（RR [95% CI]）表示，下限>1.0被认为具有统计学意义。所有p值均通过费舍尔精确检验确定。p<0.05的值被认为具有统计学意义。急性缺血性中风患者的平均血浆MPO水平为583±48 pmol/L。78例缺血性中风患者中有71例的平均血浆MPO水平高于正常上限（425±36 pmol/L，p<0.0001，（RR 8.188，[95% CI 4.038至16.600]）。12例对照的平均血浆MPO水平高于正常上限。总之，与对照相比，缺血性中风患者的血浆MPO水平在统计学上显著更高。MPO与急性缺血性中风有关，但其在发病机制中的直接作用尚未明确。MPO可被提议作为此类病变的潜在预后标志物，而非诊断标志物。MPO是一种新的生物标志物，也是未来可能的治疗靶点。
